Physician profile
John R Deforest
NPI 1003842964
$12,599.46
in general payments reported to CMS, 2019-2025
44 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $2,167 · 2021: $2,313 · 2022: $1,749 · 2023: $1,318 · 2024: $1,661 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,034.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $973.52 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $794.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $770.84 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $683.82 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Merz North America, INC. | $600.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $566.21 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $549.85 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $535.52 | 2019-2025 | |
| Mylan Specialty L.P. | $520.55 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $516.55 | 2019-2022 | |
| Amgen INC. | $492.57 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $473.51 | 2019-2022 | |
| Glaxosmithkline, LLC. | $389.85 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $306.85 | 2020-2025 | Nexletol |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deforest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.